CRAI Q3 2024 Earnings Transcript

CRA International posted record Q3 revenue of $167.7 million, up 13.7% year over year, while non-GAAP net income, EPS, and EBITDA each rose more than 50%. Management reaffirmed full-year constant-currency guidance of $670 million-$685 million revenue and 12.2%-13.0% EBITDA margin, and raised the quarterly dividend 17% to $0.49 per share. The Antitrust & Competition Economics practice grew nearly 30%, utilization improved to 76%, and year-to-date shareholder returns reached $42.2 million through dividends and buybacks.

Analysis

CRAI is now behaving less like a cyclical consulting name and more like a scarce-capacity litigation/antitrust compounder: when conversion normalizes and utilization stays elevated, incremental revenue drops through disproportionately to profit. The key second-order effect is not just stronger demand, but better operating leverage from a tighter staffing model—if management keeps headcount disciplined while lead flow remains healthy, margins can keep expanding even if top-line growth moderates.

The bigger strategic tell is practice mix. Antitrust and IP are becoming a larger share of the earnings engine just as regulatory scrutiny, AI-related transactions, and patent disputes are structurally increasing the addressable market; that gives CRAI a quasi-countercyclical growth profile versus broader consulting peers exposed to discretionary strategy work. Meanwhile, energy and financial economics provide a second demand leg tied to utility capex, grid transformation, and model-risk compliance, which should soften any slowdown in M&A-specific work.

The main risk is not demand collapse; it is normalization. If junior attrition re-accelerates, or if management is forced to rebuild bench faster than pipeline growth justifies, utilization and margins will mean-revert quickly. DSO is also a mild watch item: this business can look like a cash generator until collections slip seasonally or a few large matters stretch billing cadence, which would matter more now that capital returns are running ahead of earnings growth.

Key Decisions for Investors

• Long CRAI versus short a lower-quality consulting peer basket over the next 3-6 months: the spread should favor CRAI if utilization stays in the mid-70s and the mix continues tilting toward litigation-heavy practices.
• Buy CRAI on any 5-8% pullback rather than chasing the name after a strong quarter; the setup is fundamentally backed, but the stock is likely to consolidate as investors handicap guidance durability and DSO seasonality.
• Express a bullish view with a call spread in the next 1-2 quarters: upside is tied to margin surprise more than revenue, so structure around earnings rerating rather than linear top-line growth.
• Pair long CRAI / short a broad small-cap consulting or professional-services ETF to isolate the firm-specific operating leverage from any macro slowdown in discretionary advisory spend.
• Trim or hedge after a sharp post-earnings rerating if the market begins pricing 2025 growth as fully secular; the best entry is when investors treat the quarter as unsustainable, not when consensus extrapolates it.